Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | UTS2R | Q9UKP6 | 9/20 | 0.46 |
| ▸ | F2 | P00734 | 2/20 | 0.41 |
| ▸ | F10 | P00742 | 1/20 | 0.41 |
| ▸ | F7 | P08709 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | DRD4 | P21917 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3047611 | 1.00 | MEN1 (0.47) | MEN1KMT2AALDH1A1UTS2RF2 | |
| SCHEMBL3050028 | 0.91 | ACHE (0.47) | F2F10F7ACHE | |
| SCHEMBL3055262 | 0.91 | ACHE (0.47) | F2F10F7ACHE | |
| SCHEMBL3058126 | 0.91 | ACHE (0.47) | F2F10F7ACHE | |
| SCHEMBL3055358 | 0.89 | MAPK14 (0.47) | KMT2AF2F10F7ACHE | |
| SCHEMBL3055134 | 0.89 | MAPK14 (0.47) | KMT2AF2F10F7ACHE | |
| SCHEMBL3047609 | 0.87 | MEN1 (0.49) | MEN1KMT2AALDH1A1UTS2RF2 | |
| SCHEMBL3047603 | 0.87 | MEN1 (0.49) | MEN1KMT2AALDH1A1UTS2RF2 | |
| SCHEMBL3040851 | 0.86 | NPY5R (0.41) | ALDH1A1UTS2RDRD4 | |
| SCHEMBL3053994 | 0.86 | NPY5R (0.41) | ALDH1A1UTS2RDRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100222396-A1 | 4-ARYL-BUTANE-1,3-DIAMIDES | NOVARTIS AG (CH) | 2010-09-02 | — | — | US | claimed |
| US-20100222396-A1 | 4-ARYL-BUTANE-1,3-DIAMIDES | NOVARTIS AG (CH) | 2010-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222396-A1 | 4-ARYL-BUTANE-1,3-DIAMIDES | CYP11B2, CYP11B1, BBC3 | MEN1 507/4885KMT2A 3047/4885ALDH1A1 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.